Full-Time
Confirmed live in the last 24 hours
Develops RNAi-based therapies for genetic diseases
$250k - $340kAnnually
Senior
Pasadena, CA, USA + 1 more
More locations: San Diego, CA, USA
Willingness to relocate to either San Diego or Pasadena, CA.
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse the progression of diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure deep and lasting effects on target genes. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. Their goal is to provide new options for patients suffering from genetic disorders, and they generate revenue through partnerships, licensing agreements, and future sales of their therapies after regulatory approval.
Company Stage
IPO
Total Funding
$4.7M
Headquarters
Pasadena, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?